Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study

Circulation

Volumn 106, Issue 22, 2002, Pages 2812-2818

  Longenecker, J Craig ^a   Klag, Michael J ^a   Marcovina, Santica M ^a,b   Powe, Neil R ^a   Fink, Nancy E ^a   Giaculli, Federico ^a,b,c   Coresh, Josef ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Kidney; Lipoproteins; Mortality

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A; LIPID;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; APOLIPOPROTEINS; APOPROTEIN(A); BIOLOGICAL MARKERS; BLOTTING, WESTERN; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEIN(A); MALE; MIDDLE AGED; PARTICLE SIZE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 0037180457     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000038946.91899.BB     Document Type: Article

References (20)

1. Special report from the National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32:S1-S199.
2. United States Renal Data System. USRDS 1999 Annual Data Report. Bethesda, Md: The National Institutes of Health, NIDDK; 1999.
3. Marcovina SM, Albers JJ, Wijsman E, et al. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res. 1996;37:2569-2585.
4. Marcovina SM, Albers JJ, Gabel B, et al. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41:246-255.
5. Kronenberg F, Konig P, Neyer U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995;6:110-120.
6. Kronenberg F, Neyer U, Lhotta K, et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: A prospective follow-up. J Am Soc Nephrol. 1999;10:1027-1036.
7. Cressman MD, Abood D, O'Neil J, et al. Lp(a) and premature mortality during chronic hemodialysis treatment. Chem Phys Lipids. 1994;67-68:419-427.
8. Goldwasser P, Michel MA, Collier J, et al. Prealbumin and lipoprotein(a) in hemodialysis: Relationships with patient and vascular access survival. Am J Kidney Dis. 1993;22:215-225.
9. Koch M, Kutkuhn B, Grabensee B, et al. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: A prospective study in 412 subjects. Nephrol Dial Transplant. 1997;12:2603-2611.
10. Marcovina SM, Zhang ZH, Gaur VP, et al. Identification of 34 apolipoprotein(a) isoforms: Differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun. 1993;191:1192-1196.
11. Marcovina SM, Hobbs HH, Albers JJ. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: Basis for a standardized isoform nomenclature. Clin Chem. 1996;42:436-439.
12. Greenfield S, Sullivan L, Silliman RA, et al. Principles and practice of case mix adjustment: Applications to end stage renal disease. Am J Kidney Dis. 1994;24:298-307.
13. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease: Meta-analysis of prospective studies. Circulation. 2000;102:1082-1085.
14. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000;283:1845-1852.
15. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arteriosclerosis Thromb Vasc Biol. 1997;17:239-245.
16. Klausen IC, Sjol A, Hansen PS, et al. Apolipoprotein(a) isoforms and coronary heart disease in men: A nested case-control study. Atherosclerosis. 1997;132:77-84.
17. Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: Prospective results from the Bruneck study. Circulation. 1999;100:1154-1160.
18. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen. Biochemistry. 1989;28:2370-2374.
19. Hervio L, Girard-Globa A, Durlach V, et al. The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin. Eur J Clin Invest. 1996;26:411-417.
20. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis. 1996;27:1-25.